Display Settings:

Format

Send to:

Choose Destination
    Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3378-82. Epub 2005 Feb 22.

    Immunogenicity in humans of an edible vaccine for hepatitis B.

    Source

    Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

    Abstract

    A double-blind placebo-controlled clinical trial evaluated the immunogenicity of hepatitis B surface antigen (HBsAg) expressed in potatoes and delivered orally to previously vaccinated individuals. The potatoes accumulated HBsAg at approximately 8.5 microg/g of potato tuber, and doses of 100 g of tuber were administered by ingestion. The correlate of protection for hepatitis B virus, a nonenteric pathogen, is blood serum antibody titers against HBsAg. After volunteers ate uncooked potatoes, serum anti-HBsAg titers increased in 10 of 16 volunteers (62.5%) who ate three doses of potatoes; in 9 of 17 volunteers (52.9%) who ate two doses of transgenic potatoes; and in none of the volunteers who ate nontransgenic potatoes. These results were achieved without the coadministration of a mucosal adjuvant or the need for buffering stomach pH. We conclude that a plant-derived orally delivered vaccine for prevention of hepatitis B virus should be considered as a viable component of a global immunization program.

    PMID:
    15728371
    [PubMed - indexed for MEDLINE]
    PMCID: PMC549291
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Fig. 1.

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk